UroGen Pharma Submits NDA To FDA For Its Investigational Drug UGN-103 For Intravesical Solution
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the submission of a New Drug Application
UroGen Pharma asked the FDA permission to sell a new medicine for bladder cancer called UGN-103. When a company takes this big step, it shows they believe in their drug, so watch whether the FDA says yes or no—that will tell you if the medicine is ready to help patients and make money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.